Novo Nordisk A/s Class B · OMXCOP:NOVO_B
Novo Nordisk A/s Class B — Investor Day (September 2026)
16 slides from Novo Nordisk A/s Class B's investor day presentation, Sep 21, 2026
Slide 1: US Operations
US Operations Jamey Millar CMD26 EVP, US Operations Edward Cinca SVP, Marketing & Patient Solutions Capital Markets Day 21 September
Slide 2: Forward-looking statements
2 US Operations Forward-looking statements Novo Nordisk’s statutory Annual Report 2025, Form 20-F, any quarterly financial reports, the materials displayed and other information provided (orally or in writing) at this Capital Markes Day as well as written information released, shown, or oral stateme
Slide 3: US Operations continues to drive GLP-1 volume growth and gain market share in obesity
3 US Operations US Operations continues to drive GLP-1 volume growth and gain market share in obesity, in a year of pricing headwinds Uptake of Novo GLP-1s in the US continues Novo has gained market share within US Operations sales are impacted by 2026 to increase branded obesity medications pricing
Slide 4: Clear strategy is in place to support sales growth in US Operations over the mid- to long term
4 US Operations Clear strategy is in place to support sales growth in US Operations over the mid- to long term Key strategic priorities across the corporate strategy in US Operations Operational priorities to deliver on the strategy Drive Ozempic® uptake by reinforcing differentiated outcomes Diab
Slide 5: Novo continues efforts to improve reimbursed access in obesity
5 US Operations Novo continues efforts to improve reimbursed access in obesity Commercial obesity medication coverage is inferior to other Novo continues to work on securing long-term durable access and chronic disease areas, with access being cumbersome for many reimbursement in both private and pu
Slide 6: Consumer dynamics are driving obesity market growth, as direct-to-patient models expand access
6 US Operations Consumer dynamics are driving obesity market growth, as direct-to-patient models expand access Wegovy® franchise channel mix has Direct-to-patient models are redefining obesity care and driving growth for Novo changed significantly since 2025 Strategy is built on a multi-channel ecos
Slide 7: The recently launched Wegovy subscription model is gaining traction on the Ro platform
7 US Operations The recently launched Wegovy® subscription model is gaining traction on the Ro® platform Adoption of Wegovy® subscription model on the Ro® platform Wegovy® subscription model drives greater patient adherence and titration Active subscriptions Consumers on subscription plans on averag
Slide 8: Novocare 2.0 is evolving into an integrated ecosystem to strengthen consumer engagement
8 US Operations Novocare® 2.0 is evolving into an integrated ecosystem to strengthen consumer engagement Novocare® to become a cross-brand ecosystem connecting The ambition with Novocare® is to create a best-in-class, unified access, support and engagement end-to-end consumer experience Support and
Slide 9: Wegovy pill launch momentum builds on competitive clinical profile and commercial readiness
9 US Operations Wegovy® pill launch momentum builds on competitive clinical profile and commercial readiness across US Operations Competitive clinical profile of Commercial execution enabled rapid Uptake continues to outpace oral Wegovy® pill launch and uptake momentum competitor Weekly TRx (‘000s)
Slide 10: Wegovy pill drives market expansion, supported by real-world evidence of sustained weight loss
10 US Operations Wegovy® pill drives market expansion, supported by real-world evidence of sustained weight loss after six months Insights from WeGoTogether® and Ro® show real-world weight Wegovy® pill uptake continues to be primarily driven by market loss with Wegovy® pill is higher than the clinic
Slide 11: Wegovy pill and HD launches are unlocking growth in a market with low treatment rate
11 US Operations Wegovy® pill and HD launches are unlocking growth in a market with low treatment rate Less than 10% are treated for obesity in The Wegovy® franchise is NBRx leader in USO will continue to drive uptake for the the US today the OM category with 55% market share Wegovy® franchise Milli
Slide 12: CagriSema is expected to expand the Novo obesity portfolio
12 US Operations CagriSema is expected to expand the Novo obesity portfolio and introduce the GLP-1 and amylin biology as potential first in class CagriSema introduces next-generation of weight loss medication, Commercial readiness to secure a successful launch of CagriSema powered by the GLP-1 + am
Slide 13: US GLP-1 diabetes market remains attractive, with commercial focus on driving Ozempic preference
13 US Operations US GLP-1 diabetes market remains attractive, with commercial focus on driving Ozempic® preference The US GLP-1 diabetes market offers Ozempic® injectable TRx trend has Commercial focus on Ozempic® runway for growth stabilised in 2026 preference and leveraging pill launch Million peo
Slide 14: Ozempic pill launch is driving new patients to the franchise
14 US Operations Ozempic® pill launch is driving new patients to the franchise, with the potential to expand the oral GLP-1 type 2 diabetes market Ozempic® pill transition is progressing, with all new patients now Launch of Ozempic® pill creates opportunity to expand the oral starting directly on th
Slide 15: US Operations is set to execute on up to 12 potential launches over the next 5 years
15 US Operations US Operations is set to execute on up to 12 potential launches over the next 5 years The future US portfolio is expected to expand patient reach across all therapeutic areas Asset 2027 2028 2029 2030 Ozempic® pill 25 mg Launch CagriSema Launch Diabetes Zenagamtide Launch Oral zenaga
Slide 16: The underpenetrated US obesity market offers long runway for the Wegovy franchise
16 US Operations 1 2 3 The underpenetrated US obesity market Ozempic® pill launch is driving new patients US Operations to potentially execute on 12 offers long runway for the Wegovy® franchise to the franchise, in a market that remains launches over next 5 years, providing a and future products att